GlassScriptPhysician profile
Jennifer Dodman
NPI 1407323298
$2,231.48
in general payments reported to CMS, 2019-2025
28 companies · $669 in 2025
The $669 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $711 · 2023: $358 · 2024: $493 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $261.48 | 2022-2024 | Ultomiris |
| Nevro Corp. | $210.87 | 2022-2024 | Senza |
| Abbvie INC. | $161.51 | 2024-2025 | |
| Pfizer INC. | $133.27 | 2024-2025 | |
| Orthofix Medical, INC. | $129.55 | 2023 | Spinal-Stim, Spinal-Stim |
| Takeda Pharmaceuticals U.S.A., INC. | $123.13 | 2022 | |
| Medical Device Business Services, INC. | $122.62 | 2022 | |
| Abbott Laboratories | $108.61 | 2022-2023 | Octrode |
| E.R. Squibb & Sons, L.L.C. | $101.81 | 2022 | |
| Amneal Pharmaceuticals LLC | $97.85 | 2025 | Ongentys, Crexont |
| Merz Pharmaceuticals, LLC | $95.16 | 2024-2025 | Inbrija, Xeomin |
| Globus Medical, INC. | $88.57 | 2022-2025 | Senza |
| Argenx US, INC. | $79.15 | 2024-2025 | Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $66.31 | 2025 | Austedo Xr |
| Stryker Corporation | $58.22 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $42.88 | 2024-2025 | Gocovri |
| Lilly USA, LLC | $41.39 | 2024-2025 | Emgality, Kisunla, Amyvid |
| Lundbeck LLC | $40.77 | 2024-2025 | Vyepti |
| Neurocrine Biosciences, INC. | $38.85 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $38.10 | 2025 | Wainua |
| Sk Life Science, INC. | $34.31 | 2024 | |
| Csl Behring | $29.09 | 2025 | Hizentra |
| Biohaven Pharmaceutical Holding Company LTD. | $28.21 | 2022 | |
| Inspire Medical Systems, INC. | $24.94 | 2024 | Inspire |
| Jazz Pharmaceuticals INC. | $22.27 | 2025 | |
| Averitas Pharma INC. | $21.17 | 2025 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $16.68 | 2025 | Rexulti |
| Biogen, INC. | $14.71 | 2025 | Leqembi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Dodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.